Artiva Biotherapeutics is a company that develops off-the-shelf cell therapies designed to treat hematologic malignancies or solid tumors. Its pipeline of targeted product candidates exploits the innate biology and safety features of natural killer (NK) cells, helping patients with enhanced antibody combination therapy and genetic engineering.